Vertex CMO Jeffrey Chodakewitz is hitting the exit doors. What's next?
Just days after the launch of Vertex’s big Phase III study of its lead cystic fibrosis triple therapy, the big biotech is bidding farewell to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
